Two Protagonist Therapeutics Insiders Sold More Than $8M as Trial Milestones Moved the Story Forward
Two Protagonist Therapeutics insiders sold more than $8M of PTGX stock in late March as the biotech moved deeper into a milestone-rich phase with regulatory and trial catalysts ahead.
Ali Asif and Dinesh Patel together sold more than $8M of Protagonist Therapeutics (PTGX) stock in late March filings. The visible Form 4 activity around Protagonist Therapeutics (PTGX) landed on 2026-03-26, and the filings matter because Protagonist entered 2026 with late-stage milestones, regulatory progress, and partner-backed trial work putting the biotech back under a brighter spotlight.
What Happened
The filings showed late-March exercise-and-sell activity from more than one insider, not just an isolated single-person trade. That makes the story more interesting, even if the mechanics still matter.
| Date | Code | Action | Shares | Value | Shares After |
|---|---|---|---|---|---|
| 2026-03-26 | S | sold | 24,765 | $2.6M | 60753 |
| 2026-03-25 | S | sold | 54,641 | $5.5M | 524938 |
| 2026-03-24 | S | sold | 59 | $6K | 524938 |
Why This Matters
Biotech insiders often sell after major reratings, and the meaning depends on whether the pipeline is advancing or stalling. In this case, the operating backdrop remained milestone-rich rather than broken.
Recent coverage focused on regulatory and clinical milestones moving forward in 2026, which helps explain why the stock became an attractive place for insiders to take some liquidity.
Ownership Context
These filings are best read as monetization after milestone-driven appreciation, not as evidence that the therapeutic or regulatory setup has collapsed.
The most relevant internal pages for following this story are Ali Asif, PATEL DINESH V PH D and Protagonist Therapeutics. Large disclosed holders include VANGUARD GROUP INC, VANGUARD GROUP INC.
What To Watch Next
- Whether upcoming trial and regulatory milestones keep validating the elevated valuation.
- Whether additional insiders join the selling pattern in the next few weeks.
- How the stock behaves once the milestone calendar becomes the only thing left supporting momentum.
Related Pages On 13F Insight
Protagonist Therapeutics (PTGX), Ali Asif, Dinesh Patel, Tempus AI (TEM), VANGUARD GROUP INC, VANGUARD GROUP INC
Bottom Line
The filings matter because they were clustered and sizable, but the broader read is still milestone monetization in a biotech that retains event risk on both the upside and the downside.
Questions Readers Actually Ask
Why does a multi-insider PTGX sale matter more than one isolated sale?
Because multiple insiders selling in the same window can change how investors assess timing and sentiment.
Does this mean Protagonists pipeline is failing?
No. The recent external backdrop still revolves around advancing milestones and regulatory progress.
What should investors watch next?
Watch the milestone calendar and whether additional insider sales follow the late-March cluster.
Related Research
Explore all researchJanus Henderson (WhaleScore 75.50) opened 67 new positions while exiting 67 in Q4 2025 — a 13.4% turnover rate signaling active repositioning. New biotech/med-device bets (ISRG, GPCR, PTGX) hint at a healthcare conviction thesis.
Mar 30, 2026
Simplex Trading reported a $177.41B Q4 2025 13F, but the filing reads less like a stock portfolio and more like an options-heavy market-structure book. That distinction is the whole story.
Apr 1, 2026
Arrowstreet Capital's systematic models triggered one of Q4 2025's most aggressive Apple trims (-38% shares) while more than doubling Google. With 93 new positions and $170.74B in 13F assets, here's what the quant signals are saying.
Mar 30, 2026
Q1 2026 13F filings are due May 15, 2026. Track Berkshire, Millennium, Bridgewater and more. See expected filing dates, AI/sector themes, and how to access data the moment it drops.
Mar 31, 2026
Scotiabank's $131.31B investment arm entered 114 new positions in Q4 2025 while trimming its dominant internal fund by 25% — one of the most aggressive quarterly reshuffles among top-100 filers.
Mar 30, 2026